Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 389

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Colchicine for Recurrent Pericarditis (CORP): A Randomized Trial

Open access
Imazio, Massimo, Brucato, Antonio, Cemin, Roberto, Ferrua, Stefania, Belli, Riccardo, Maestroni, Silvia, Trinchero, Rita, Spodick, David H., Adler, Yehuda, on behalf of the CORP (COlchicine for Recurrent Pericarditis) Investigators* · 2011 · Annals of Internal Medicine

Abstract

BACKGROUND: Recurrence is the most common complication of pericarditis, affecting 10% to 50% of patients. OBJECTIVE: To evaluate the efficacy and safety of colchicine for the secondary prevention of recurrent pericarditis. DESIGN: Prospective, randomized, double-blind, placebo-controlled multicenter trial. (ClinicalTrials.gov registration number: NCT00128414) SETTING: 4 general hospitals in urban areas of Italy. PATIENTS: 120 patients with a first recurrence of pericarditis. INTERVENTION: In addition to conventional treatment, patients were randomly assigned to receive either placebo or colchicine, 1.0 to 2.0 mg on the first day followed by a maintenance dose of 0.5 to 1.0 mg/d, for 6 months. MEASUREMENTS: The primary study end point was the recurrence rate at 18 months. Secondary end points were symptom persistence at 72 hours, remission rate at 1 week, number of recurrences, time to first recurrence, disease-related hospitalization, cardiac tamponade, and rate of constrictive pericarditis. RESULTS: At 18 months, the recurrence rate was 24% in the colchicine group and 55% in the placebo group (absolute risk reduction, 0.31 [95% CI, 0.13 to 0.46]; relative risk reduction, 0.56 [CI, 0.27 to 0.73]; number needed to treat, 3 [CI, 2 to 7]). Colchicine reduced the persistence of symptoms at 72 hours (absolute risk reduction, 0.30 [CI, 0.13 to 0.45]; relative risk reduction, 0.56 [CI, 0.27 to 0.74]) and mean number of recurrences, increased the remission rate at 1 week, and prolonged the time to subsequent recurrence. The study groups had similar rates of side effects and drug withdrawal. LIMITATION: Multiple recurrences and neoplastic or bacterial causes were excluded. CONCLUSION: Colchicine is safe and effective for secondary prevention of recurrent pericarditis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-155-7-201110040-00359

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 389

Metadata

Authors
Imazio, M., Brucato, A., Cemin, R., Ferrua, S., Belli, R., Maestroni, S., Trinchero, R., Spodick, D. H., Adler, Y., & on behalf of the CORP (COlchicine for Recurrent Pericarditis) Investigators*
Venue
Annals of Internal Medicine
Published
2011-10-04
Volume
155
Issue
7
Pages
409-414
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W1995437293
Cited by
389
References
15
FWCI
14.97
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Colchicine for Recurrent Pericarditis (CORP): A Randomized Trial. https://app.cochat.ai/papers/10.7326/0003-4819-155-7-201110040-00359
The paper
Imazio, M., Brucato, A., Cemin, R., Ferrua, S., Belli, R., Maestroni, S., Trinchero, R., Spodick, D. H., Adler, Y., & on behalf of the CORP (COlchicine for Recurrent Pericarditis) Investigators*. (2011). Colchicine for Recurrent Pericarditis (CORP): A Randomized Trial. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-155-7-201110040-00359

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.